Viral Inactivation in Bioprocess Development - METTLER TOLEDO
Seminar

Viral Inactivation in Bioprocess Development

Automated Solutions for Optimization and Control of Low pH Viral Inactivation

Viral inactivation is usually achieved by altering the physical structure and/or integrity of any viral structures or content through chemical, physical, or even energetic methods. Developing a viral inactivation process generally falls back on manual legacy methods which present challenges and shortcomings for modern bioprocesses, especially when considering need for remote or unattended operations.

Process development for a typical viral inactivation requires traceable pH titration for volume and target pH. However, legacy manual methods require significant resource and time for processes which are tedious, repetitive, labor intensive, and error prone. These are all conditions which automation and digitalization seek to mitigate.

Users who adopt and implement EasyMax for automated low pH viral inactivation process development demonstrate significant value and benefits. Scientists can capture the same quantity and quality of information in 75-80% fewer runs compared to using legacy tools. In addition, scientists increase productivity with parallel, independent runs while significantly reducing the number of man-hours in front of the workstation. Project timelines are accelerated and costs are reduced.

About the Presenter

Tyler Gable

Market Development Manager for Biologics, METTLER TOLEDO

Tyler Gable received two Bachelor of Science degrees, in Chemistry and in Biotechnology, and furthered his education with a PhD in Molecular Medicine and Molecular Biology from the University of Maryland, Baltimore. His research focused on the role of 'piRNA-like' in non-small cell adenocarcinoma and squamous cell carcinoma, developing clinical RNA-blood screens for non-small cell adenocarcinoma and squamous cell carcinoma, companion diagnostic methods for prediction of chemotherapy resistance, as well as early development of 'piRNA-like' humoral delivery mechanisms. Tyler began his career with 5 years at Jubilant Hollister-Stier, and joined METTLER TOLEDO as a Technology and Applications Consultant, where he lead PAT development for new applications in biopharmaceutical bioprocessing. Now, as a Market Development Manager for Biologics, Tyler bridges his experience from clinical research and development with his knowledge of large molecule manufacturing, and guides strategy for novel application of PAT to bioprocesses.